DR info

Clinical trials : 33 / Drugs : 41 - (DrugBank : 21) / Drug target genes : 22 - Drug target pathways : 123

Drugs and their primary sponsors and trial info

Best Supportive Care (BSC)
   Janssen Research & Development, LLC
      2010   Phase 2   NCT01024036   Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Jordan;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Poland;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
Bevacizumab
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States;
Bortezomib
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00092222   United States;
   Peking Union Medical College Hospital
      2019   Phase 2   NCT03982771   China;
CNTO 328
   Centocor, Inc.
      2005   Phase 1   NCT00412321   United States;
CNTO328
   Centocor BV
      2010   Phase 2   EUCTR2009-012380-34-FR   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
      2009   Phase 2   EUCTR2009-012380-34-ES   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
   Janssen Biologics B.V.
      2010   Phase 2   EUCTR2009-012380-34-NL   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
   Janssen Biologics BV
      2010   -   EUCTR2009-012380-34-HU   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
   Janssen-Cilag International N.V.
      2010   -   EUCTR2009-012380-34-DE   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
   Janssen-Cilag International N.V.
      2013   Phase 2   EUCTR2010-022837-27-GB   Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States;
      2012   Phase 2   EUCTR2010-022837-27-ES   Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States;
      2012   Phase 2   EUCTR2010-022837-27-DE   Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States;
      2012   Phase 2   EUCTR2010-022837-27-BE   Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States;
      2010   Phase 2   EUCTR2009-012380-34-GB   Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2010   Phase 2   EUCTR2009-012380-34-BE   Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
CX-4945 oral formulation
   Cylene Pharmaceuticals
      2009   Phase 1   NCT00891280   United States;
Cetuximab
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States;
Chimeric murine human anti-IL-6 monoclonal antibody
   Centocor BV
      2010   Phase 2   EUCTR2009-012380-34-FR   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
      2009   Phase 2   EUCTR2009-012380-34-ES   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
   Janssen Biologics B.V.
      2010   Phase 2   EUCTR2009-012380-34-NL   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
   Janssen Biologics BV
      2010   -   EUCTR2009-012380-34-HU   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
   Janssen-Cilag International N.V.
      2010   -   EUCTR2009-012380-34-DE   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
   Janssen-Cilag International N.V.
      2010   Phase 2   EUCTR2009-012380-34-GB   Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2010   Phase 2   EUCTR2009-012380-34-BE   Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
Cyclophosphamide
   Fred Hutchinson Cancer Research Center
      2019   Phase 1   NCT03864419   Uganda;United States;
   National Cancer Institute (NCI)
      2014   Phase 1/Phase 2   NCT02228512   United States;
      2004   Phase 2   NCT00092222   United States;
   Peking Union Medical College Hospital
      2019   Phase 2   NCT03982771   China;
Dexamethason
   Peking Union Medical College Hospital
      2019   Phase 2   NCT03982771   China;
Doxorubicin
   National Cancer Institute (NCI)
      2014   Phase 1/Phase 2   NCT02228512   United States;
Doxorubicin Hydrochloride
   Fred Hutchinson Cancer Research Center
      2019   Phase 1   NCT03864419   Uganda;United States;
Etoposide
   Fred Hutchinson Cancer Research Center
      2019   Phase 1   NCT03864419   Uganda;United States;
   National Cancer Institute (NCI)
      2014   Phase 1/Phase 2   NCT02228512   United States;
      2004   Phase 2   NCT00092222   United States;
   UNC Lineberger Comprehensive Cancer Center
      2021   Phase 2   NCT04585893   Malawi;
Filgrastim (G-CSF)
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00092222   United States;
Interferon-alpha
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00092222   United States;
Lenalidomide
   Department of Hematology, Jiangsu Provincial People's Hospital
      2021   Phase 4   ChiCTR2100048364   China;
Liposomal Doxorubicin
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00092222   United States;
Methotrexate
   Fred Hutchinson Cancer Research Center
      2019   Phase 1   NCT03864419   Uganda;United States;
Nelfinavir
   Sidney Kimmel Comprehensive Cancer Center
      2014   Phase 0   NCT02080416   United States;
Pomalidomide
   National Cancer Institute (NCI)
      2014   Phase 1/Phase 2   NCT02228512   United States;
Prednisone
   Fred Hutchinson Cancer Research Center
      2019   Phase 1   NCT03864419   Uganda;United States;
   National Cancer Institute (NCI)
      2014   Phase 1/Phase 2   NCT02228512   United States;
      2004   Phase 2   NCT00092222   United States;
Rituximab
   Department of Hematology, Jiangsu Provincial People's Hospital
      2021   Phase 4   ChiCTR2100048364   China;
   French National Agency for Research on AIDS and Viral Hepatitis
      2003   Phase 2   NCT00127569   -
   National Cancer Institute (NCI)
      2014   Phase 1/Phase 2   NCT02228512   United States;
      2004   Phase 2   NCT00092222   United States;
   UNC Lineberger Comprehensive Cancer Center
      2021   Phase 2   NCT04585893   Malawi;
Rituximab and Hyaluronidase Human
   Fred Hutchinson Cancer Research Center
      2019   Phase 1   NCT03864419   Uganda;United States;
Siltuximab
   EusaPharma (UK) Limited
      2021   Phase 2   NCT04838860   United States;
   Janssen Research & Development, LLC
      2011   Phase 2   NCT01400503   Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States;
      2010   Phase 2   NCT01024036   Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Jordan;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Poland;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
Sirolimus
   Kawakami Atsushi
      2020   Phase 2   JPRN-jRCT2071190029   Japan;
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00092222   United States;
   University of Pennsylvania
      2019   Phase 2   NCT03933904   United States;
Suramin
   University of Arkansas
      1995   Phase 2   NCT00002652   United States;
Temsirolimus
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States;
Thalidomide, cyclophosphamide and prednisone
   Peking Union Medical College Hospital
      2017   Phase 2   NCT03043105   China;
Tocilizumab
   National Cancer Institute (NCI)
      2011   Phase 2   NCT01441063   United States;
Tocilizumab [RoActemra/Actemra]
   Hoffmann-La Roche
      2006   Phase 1   NCT01183598   United States;
Valganciclovir
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00092222   United States;
   University of Washington
      2008   Phase 4   NCT00361933   United States;
Valganciclovir (VGC)
   National Cancer Institute (NCI)
      2011   Phase 2   NCT01441063   United States;
Vincristine
   Fred Hutchinson Cancer Research Center
      2019   Phase 1   NCT03864419   Uganda;United States;
   National Cancer Institute (NCI)
      2014   Phase 1/Phase 2   NCT02228512   United States;
      2004   Phase 2   NCT00092222   United States;
Zanubrutinib
   Peking Union Medical College Hospital
      2021   Phase 2   NCT04743687   China;
Zidovudine
   National Cancer Institute (NCI)
      2011   Phase 2   NCT01441063   United States;
      2004   Phase 2   NCT00092222   United States;